XW053T9
Introduction Peripheral Artery to New Technology Group 9 with Melphalan Hydrochloride Antineoplastic, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 5 Peripheral Artery |
| Approach | 3 Percutaneous |
| Device | T Melphalan Hydrochloride Antineoplastic |
| Qualifier | 9 New Technology Group 9 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Peripheral Artery
Peripheral arteries supply oxygenated blood to the limbs and other non-central regions, and Introduction procedures targeting them under New Technology involve delivering a novel substance directly into arterial circulation at a location outside the central vasculature. This route is used when an agent is intended to act locally within a limb's vascular bed or when arterial rather than venous delivery is required for the substance's mechanism, such as certain regional therapies. Because peripheral arteries are smaller and carry higher pressure than veins, access technique and catheter selection differ accordingly, and the risk profile includes concerns like vessel injury or distal ischemia. Correct coding depends on confirming both the arterial nature of the vessel and its peripheral, rather than central, location.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Melphalan Hydrochloride Antineoplastic
This value represents melphalan hydrochloride delivered via a specialized hepatic perfusion system to treat ocular (uveal) melanoma that has metastasized to the liver, isolating and concentrating the chemotherapy within hepatic circulation. It differs from systemic antineoplastic agents such as quizartinib by relying on a regional delivery device rather than standard intravenous infusion, limiting systemic exposure while maximizing local tumor drug concentration.
Qualifier: New Technology Group 9
Group 9 is the seventh-position qualifier used in the New Technology section to mark a device, substance, or technique as belonging to the 2022 annual cohort of new technology add-on codes. It has no clinical meaning of its own beyond that vintage tag, so coders rely on the specific table and body system to know what procedure it applies to. It is distinguished from Group 8 and Group 10 purely by the fiscal year the technology was approved for separate identification.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.